Načítá se...
Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada
BACKGROUND: In the phase iii palette trial of pazopanib compared with placebo in patients with advanced or metastatic soft-tissue sarcoma (sts) who had received prior chemotherapy, pazopanib treatment was associated with improved progression-free survival (pfs). We used an economic model and data fr...
Uloženo v:
| Vydáno v: | Curr Oncol |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Multimed Inc.
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4257119/ https://ncbi.nlm.nih.gov/pubmed/25489263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.21.1899 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|